Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · IEX Real-Time Price · USD
8.43
-0.48 (-5.39%)
Jan 27, 2022 3:58 PM EST - Market open

Company Description

Entrada Therapeutics aims to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines and aims to become the world’s foremost intracellular therapeutics company.

Our EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. Through our proprietary, highly versatile and modular EEV platform, we are building a robust development portfolio of EEV therapeutic candidates designed to enable the efficient intracellular delivery of therapeutics in various organs and tissues with an improved therapeutic index.

We believe that the potential success of our early programs can translate into the efficient development of additional EEV therapeutic candidates and allow us to build portfolios in rare disease, immunology and oncology.

We are initially focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Our most advanced therapeutic candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. We plan to submit an Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 in 2022.

Entrada Therapeutics, Inc.
CountryUnited States
Founded2016
IPO DateOct 29, 2021
IndustryBiotechnology
SectorHealth Care
Employees98
CEODipal Doshi

Contact Details

Address:
6 Tide Street
Boston, MA 02210
United States
Phone857-520-9158
Websiteentradatx.com

Stock Details

Ticker SymbolTRDA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$20.00
CIK Code1689375

Key Executives

NamePosition
Dipal DoshiPresident, Chief Executive Officer and Director
Nathan J. DowdenChief Operating Officer
Dr. Natarajan Sethuraman Ph.D.Chief Scientific Officer
Kory James Wentworth CPAChief Financial Officer
Karla MacDonaldVice President of Corporate Communications and Investor Relations
Dr. Jared Cohen J.D., Ph.D.General Counsel
Kerry Robert M.S.Vice President of People
Dr. Nerissa C. Kreher M.B.A., M.D., M.S.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jan 18, 20224Statement of changes in beneficial ownership of securities
Jan 13, 20224Statement of changes in beneficial ownership of securities
Dec 29, 20214Statement of changes in beneficial ownership of securities
Dec 16, 20213Initial statement of beneficial ownership of securities
Dec 16, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Dec 9, 202110-QQuarterly report [Sections 13 or 15(d)]
Dec 9, 20218-KCurrent report
Nov 12, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Nov 12, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Nov 10, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings